Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 21, 2025 20:00 ET | Source: Faraday Future

Faraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth Engines

Faraday Future is making an investment of approximately $30 million in Qualigen Therapeutics (“QLGN”); FF Founder and Co-CEO YT Jia will invest approximately $4 million (via an FFGP loan) in QLGN with...
August 01, 2023 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need...
July 24, 2023 08:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Divests FastPack® Diagnostics Business

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 ...
May 16, 2023 08:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused...
May 02, 2023 08:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
April 18, 2023 08:45 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
April 18, 2023 07:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen”...
March 21, 2023 08:35 ET | Source: Qualigen Therapeutics, Inc.

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
March 15, 2023 09:05 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
March 09, 2023 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Data demonstrates potential anti-RAS activity with Qualigen’s novel RAS small molecule in both pancreatic and breast cancer in vivo models CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) --...